Profiles

Dareen Siri, MD

Allergy and Immunology Otolaryngology-Head and Neck Surgery
747 N. Rutledge Street Springfield, IL 62702
Profiles

Jayant Acharya, MD

Neurologist and Epilepsy Specialist Neurology | Epilepsy
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Jayant Acharya, MD

Neurologist and Epilepsy Specialist Neurology | Epilepsy
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Elisabeth Robinson, MD

Sports Medicine Specialist Orthopedic Surgery | Sports Medicine
747 N. Rutledge Street 3rd Floor Springfield, IL 62702
Profiles

Elisabeth Robinson, MD

Sports Medicine Specialist Orthopedic Surgery | Sports Medicine
747 N. Rutledge Street 3rd Floor Springfield, IL 62702
News

Notification of a Potential Data Security Incident

Dear Madam/Sir: The Southern Illinois University School of Medicine, (“SIU”) is providing notice pursuant to 815 ILCS 530/25 in connection with an incident that may have involved the personal information of certain Illinois residents. This notice will be supplemented, if necessary, with any new significant facts discovered subsequent to its submission. While SIU is notifying you of this incident, SIU does not waive any rights or defenses relating to the incident or this notice. NATURE OF THE INCIDENT AND CORRECTIVE ACTIONS TAKEN SIU recently discovered that an unknown, unauthorized third party
Profiles

Amanda McDannald, DNP, FNP-C

Certified Nurse Practitioner Otolaryngology-Head and Neck Surgery
720 North Bond Street Springfield, IL 62702
Trial
Internal Medicine

COSIRA-II: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Active recruiting
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization.
Trial
Cardiology

Dal-GenE-2: A phase 3, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)

Active recruiting
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
Trial
Cardiology

Dal-GenE-2: A phase 3, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)

Active recruiting
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
Subscribe to